Abstracts Archive - Page 2067 of 2425 - ACR Meeting Abstracts

Abstract Number: 2795 • 2013 ACR/ARHP Annual Meeting
B Cell Derived Cytokines Induce Glomerular Injury in Mice
Alfred Kim¹, Shreeram Akilesh², Jeffrey Miner³ and Andrey Shaw⁴, ¹IM/Div of Rheumatology, Washington Univ School of Med, St. Louis, MO, ²Pathology, University of Washington, Seattle, WA, ³Renal Division, Washington University School of Medicine, Saint Louis, MO, ⁴Pathology & Immunology/HHMI, Washington University School of Medicine, Saint Louis, MO
Background/Purpose: Renal involvment remains the leading cause of mortality for SLE patients, and is associated with proteinuria and foot process effacement. In subsets of LN…
Abstract Number: 2756 • 2013 ACR/ARHP Annual Meeting
Serum Periostin Is Associated With Prevalent Knee Osteoarthritis and Predicts Disease Progression In Women: The Ofely Study
Jean-Charles Rousseau¹, Elisabeth Sornay-Rendu¹, Cindy Bertholon¹, Patrick Garnero² and Roland Chapurlat³, ¹INSERM UMR 1033, Lyon, France, ²INSERM, UMR 1033, Lyon and Cisbio Bioassays, Bagnols/Cèze, France, ³Service de Rhumatologie et Pathologie Osseuse, INSERM UMR 1033 and Université de Lyon, Hôpital Edouard Herriot, Lyon, France
Background/Purpose: Periostin (POSTN) is a secreted vitamin K-dependent (Gla-containing) protein produced by osteoblasts and chondrocytes. The aim of this study was to investigate the relationships…
Abstract Number: 2757 • 2013 ACR/ARHP Annual Meeting
Metabolomics For The Identification Of Urinary Biomarkers In Knee Osteoarthritis Progression
Puja Saxena¹, Richard F. Loeser², Wimal Pathmasiri³, Susan Sumner³, Daniel Beavers⁴, David J. Hunter⁵ and Stephen P. Messier⁶, ¹Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, ²Section Of Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, NC, ³Systems and Translational Sciences, NIH Eastern Regional Comprehensive Metabolomics Resource Core, Research Triangle Park, NC, ⁴Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, ⁵Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ⁶Department of Health and Exercise Science, Wake Forest University, Winston-Salem, NC
Background/Purpose: Obesity is an important risk factor for knee OA, not only due to effects of excess adipose tissue on joint loading, but also due…
Abstract Number: 2758 • 2013 ACR/ARHP Annual Meeting
Quantifying The Risk Of Incident Type II Diabetes Following Oral Glucocorticoid Therapy In Patients With Rheumatoid Arthritis: Association With Dose and Duration Of Use
William G. Dixon¹, Mohammad Movahedi², Marie-Eve Beauchamp³, David W. Ray⁴ and Michal Abrahamowicz³, ¹The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁴Institute of Human Development, Institute of Human Development, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Glucocorticoid (GC) therapy is widely used in patients with rheumatoid arthritis (RA). Its association with incident type II diabetes mellitus (DM) is accepted, but…
Abstract Number: 2759 • 2013 ACR/ARHP Annual Meeting
Can RA Registries Provide Contextual Safety Data For Modern RCTs?
Kaleb Michaud¹, Johan Askling², Hisashi Yamanaka³, Deborah Symmons⁴, Marie Holmqvist², Thomas Frisell⁵, George Reed⁶, Dimitrios A. Pappas⁷, Eiichi Tanaka⁸, Eisuke Inoue⁹, Suzanne M.M. Verstappen⁴, Christopher Garwood⁴, Laura Horne¹⁰, Kathy Lampl¹¹, Niklas Berglind¹², Stefan Franzen¹², Fredrik Nyberg¹³, Trung Tran¹⁴, Meilien Ho¹⁵ and Jeffrey D. Greenberg¹⁶, ¹Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE, ²Karolinska Institutet, Stockholm, Sweden, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁵Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁶Orthopedics, University of Massachusetts Medical School, Worcester, MA, ⁷Columbia University, New York, NY, ⁸Tokyo Women's Medical University, Tokyo, Japan, ⁹Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ¹⁰AstraZeneca, Wilmington, DE, ¹¹AstraZeneca R&D Wilmington, Wilmington, DE, ¹²AstraZeneca R&D Mölndal, Mölndal, Sweden, ¹³AstraZeneca R&D, Mölndal, Sweden, ¹⁴MedImmune LLC, Gaithersburg, MD, ¹⁵AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ¹⁶New York University School of Medicine, New York, NY
Background/Purpose: For ethical reasons, modern phase-III RCTs in rheumatoid arthritis (RA) have limited placebo exposure time, resulting in uncertainties when interpreting low frequency adverse events…
Abstract Number: 2760 • 2013 ACR/ARHP Annual Meeting
Incidence and Severity Of Myocardial Infarction In Subjects Receiving Anti Tumour Necrosis Factor Drugs For Rheumatoid Arthritis: Results From Linking the British Society For Rheumatology Biologics Register For Rheumatoid Arthritis and Myocardial Ischaemia National Audit Project
Audrey SL Low¹, Kimme L. Hyrich², Mark Lunt³, Louise K. Mercer³, Christopher Gale^4,5, Kath Watson⁶, British Society for Rheumatology Biologics Registers (BSRBR) Control Centre Consortium¹, William G. Dixon⁷, Deborah P. Symmons^3,8 and On behalf of the BSRBR⁹, ¹Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ⁴Division of Epidemiology, Centre for Epidemiology and Biostatistics, University of Leeds, Leeds, United Kingdom, ⁵Department of Cardiology,York Teaching Hospital NHS Foundation Trust, York, United Kingdom, ⁶Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁷The University of Manchester, Manchester, United Kingdom, ⁸Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁹British Society for Rheumatology, London, United Kingdom
Background/Purpose: Subjects with rheumatoid arthritis (RA) are at increased risk of myocardial infarction (MI) compared to subjects without RA, with the increased risk potentially driven…
Abstract Number: 2761 • 2013 ACR/ARHP Annual Meeting
Comparative Risks Of Herpes Zoster Among RA Patients Switching Biologics In The U.S. Medicare Program
Huifeng Yun¹, Fenglong Xie², Elizabeth S. Delzell¹, Lang Chen³, Emily Levitan¹, James Lewis⁴, Kenneth G. Saag⁵, Timothy Beukelman⁶, Kevin L. Winthrop⁷, John Baddley⁸ and Jeffrey R. Curtis⁹, ¹Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ⁸Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁹University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Several newer biologics have been approved for treatment of rheumatoid arthritis (RA) in the United States. However, their comparative risks of herpes zoster infection…
Abstract Number: 2762 • 2013 ACR/ARHP Annual Meeting
Rheumatoid and Psoriatic Arthritis Are Not Associated With Higher Risk Of Incident Diabetes Mellitus
Susan Mathew¹, Xiaoqin Tang², H. Lester Kirchner³, Mary Chester M. Wasko⁴ and Androniki Bili¹, ¹Rheumatology, Geisinger Medical Center, Danville, PA, ²Biostatistics, Geisinger Center for Health Research, Danville, PA, ³Geisinger Center for Health Research, Geisinger Health System, Danville, PA, ⁴West Penn Allegheny Health System, Temple University School of Medicine, Pittsburgh, PA
Background/Purpose: Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are chronic inflammatory conditions that are associated with increased risk of insulin resistance and cardiovascular disease…
Abstract Number: 2763 • 2013 ACR/ARHP Annual Meeting
Carotid Atherosclerosis As a Predictor Of Mortality In Rheumatoid Arthritis
Inmaculada del Rincon¹, Roy W. Haas², Jose Felix Restrepo³, Daniel F. Battafarano⁴, Daniel H. O'Leary⁵, Emily Molina¹ and Agustin Escalante⁶, ¹Rheumatology, University of Texas Health Science Center, San Antonio, TX, ²Dept. of Medicine-Rheumatology, University of Texas Health Science Center, San Antonio, TX, ³Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ⁴Medicine / MCHE-MDR, Brooke Army Medical Ctr, San Antonio, TX, ⁵Radiology, Tufts University-Boston Campus, Boston, MA, ⁶Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: Patients with rheumatoid arthritis (RA) have higher mortality than do persons of the same age and sex without RA. This is due in part…
Abstract Number: 2764 • 2013 ACR/ARHP Annual Meeting
Combination of Intra-Articular Steroid Injection and Tocilizumab More Effective Than Tocilizumab in Rapid Radiographic Progression Patients With Rheumatoid Arthritis. A Randomized, Open Label, x Ray Reader Blinded Study
Kensuke Kume¹, Kanzo Amano¹, Susumu Yamada¹, Toshikatsu Kanazawa², Hiroshi Komori³, Hiroyuki Ohta⁴, Noriko Kuwaba⁵ and Kazuhiko Hatta⁶, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²rheumatology, hiroshima clinic, hiroshima, Japan, ³internal medicine, hiroshima clinic, hiroshima, Japan, ⁴Medical Research, hiroshima clinic, Hiroshima, Japan, ⁵Medical Research, Sanki Clinical Link, Hiroshima, Japan, ⁶Rheumatology, Hatta Clinic, Kure, Japan
Background/Purpose: Treatment of rheumatoid arthritis (RA) should aim at full remission. However, recent publications described rapid radiographic progression (RRP) existed despite initial biologics and methotrexate…
Abstract Number: 2765 • 2013 ACR/ARHP Annual Meeting
A Double-Blind Randomized Placebo-Controlled Trial Of Lovastatin in Patients with Rheumatoid Arthritis
Cynthia Aranow¹, John J. Cush², Marcy B. Bolster³, Christopher C. Striebich⁴, Maria Dall'era⁵, Meggan Mackay⁶, Ewa Olech⁷, Tracy M. Frech⁸, J. Box⁹, Richard M. Keating¹⁰, Mary Chester M. Wasko¹¹, E. William St Clair¹², Alan Kivitz¹³, Betty Diamond¹⁴, Anne Davidson¹⁵, Meagan Spychala¹⁶, Ellen A. Goldmuntz¹⁷ and Autoimmunity Centers of Excellence¹⁸, ¹Feinstein Institute for Medical Research, Manhasset, NY, ²Baylor Research Institute and Baylor University Medical Center, Dallas, TX, ³Medicine, Medical University of South Carolina, Charleston, SC, ⁴University of Colorado Denver, Aurora, CO, ⁵Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁶Autoimmune & Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, NY, ⁷Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Internal Medicine-Division of Rheumatology, University of Utah School of Medicine, SLC, UT, ⁹Carolina Bone and Joint, Charlotte, NC, ¹⁰Rheumatology Section, The University of Chicago, Chicago, IL, ¹¹West Penn Allegheny Health System, Temple University School of Medicine, Pittsburgh, PA, ¹²Medicine, Duke Unversity Medical Center, Durham, NC, ¹³Altoona Center for Clinical Research, Duncansville, PA, ¹⁴Autoimmune & Musculoskeletal, Feinstein Institute for Medical Research, Manhasset, NY, ¹⁵Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ¹⁶Rho, Inc., Chapel Hill, NC, ¹⁷DAIT, NIAID/NIH, Bethesda, MD, ¹⁸NIAID, National Institutes of Health, Bethesda, MD
Background/Purpose: HMG -CoA reductase inhibitors (statins) are standard treatment for hyperlipidemia. In addition to lipid lowering abilities, statins exhibit multiple anti-inflammatory effects. The objectives of…
Abstract Number: 2766 • 2013 ACR/ARHP Annual Meeting
Improvement In Insulin Resistance Greater With The Use Of Infliximab Following Intensive Treatment Of Early Rheumatoid Arthritis
Lesley-Anne Bissell¹, Elizabeth Hensor², Sarah L. Mackie², Agata Burska³, Jackie L. Nam², Lukasz Kozera², Helen I. Keen⁴, Edith Villeneuve², Heike Eberl⁵, Helena Donica⁶, Philip G. Conaghan⁷, Jacqueline Andrews², Paul Emery⁸ and Ann W. Morgan², ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, Translational Research in Immune Mediated Inflammatory Diseases, the University of Leeds, Leeds, AL, United Kingdom, ⁴Leeds, Leeds, United Kingdom, ⁵Roche Molecular Diagnostics, Burgess Hill, United Kingdom, ⁶Department of Biochemical Diagnostics, Medical University of Lublin, Lublin, Poland, ⁷NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁸Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Insulin resistance (IR), N-terminal pro-brain natriuretic peptide (NT-proBNP) and total cholesterol/high density lipoprotein cholesterol ratio (TC/HDL-C) profiles have been proposed as surrogate measures of…
Abstract Number: 2767 • 2013 ACR/ARHP Annual Meeting
Tocilizumab In Combination Therapy and Monotherapy Versus Methotrexate In Methotrexate-Naive Patients With Early Rheumatoid Arthritis: Clinical and Radiographic Outcomes From a Randomized, Placebo-Controlled Trial
Gerd Burmester¹, William Rigby², Ronald F. van Vollenhoven³, Jonathan Kay⁴, Andrea Rubbert-Roth⁵, Ariella Kelman⁶, Sophie Dimonaco⁷ and Nina Mitchell⁷, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Dartmouth-Hitchcock Medical Center and Dartmouth Medical School, Lebanon, NH, ³Karolinska Institute, Stockholm, Sweden, ⁴UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ⁵University of Cologne, Cologne, Germany, ⁶Genentech, South San Francisco, CA, ⁷Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: Recent recommendations support intensive treatment of patients (pts) with early rheumatoid arthritis (RA) to achieve remission or low disease activity.1-3 Tocilizumab (TCZ) was not…
Abstract Number: 2768 • 2013 ACR/ARHP Annual Meeting
Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety In Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: 2-Year Results Of a Phase 3 Trial Of Intravenous Golimumab
Michael E. Weinblatt¹, Clifton O. Bingham III², Alan M. Mendelsohn³, Lilianne Kim⁴, Kim Hung Lo⁴, Lenore Noonan³, Daniel Baker⁴ and Rene Westhovens⁵, ¹Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Immunology, Janssen Research & Development, LLC., Spring House, PA, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵Rheumatology, University Hospital KU Leuven, Leuven, Belgium
Background/Purpose: To evaluate long-term clinical/radiographic efficacy of IV GLM 2mg/kg+MTX in active RA despite MTX through wk112. Methods: 592 pts with active RA (≥6/66 SJC,…
Abstract Number: 2769 • 2013 ACR/ARHP Annual Meeting
Clinical Remission After 52 Weeks Of Treatment Is a Predictor Of Adalimumab-Free Disease Control In Patients With Early Rheumatoid Arthritis: Hopeful 2 Study
Yoshiya Tanaka¹, Hisashi Yamanaka², Naoki Ishiguro³, Nobuyuki Miyasaka⁴, Katsuyoshi Kawana⁵, Tadamichi Kubo⁶, Aki Kuroki⁷ and Tsutomu Takeuchi⁸, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan, ⁵Abbvie, Tokyo, Japan, ⁶Post Marketing Study Group, Medical, AbbVie GK, Tokyo, Japan, ⁷Medical Affairs, AbbVie GK, Tokyo, Japan, ⁸Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Although it is possible to achieve remission or low disease activity (LDA) with the combination of methotrexate (MTX) and biologics for many patients with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].